Not applicableStudy completedNCT00900302What this trial is testingOX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With CancerWho this might be right forCancer OHSU Knight Cancer Institute 98
Early research (Phase 1)Study completedNCT00020579What this trial is testingMS-275 in Treating Patients With Advanced Solid Tumors or LymphomaWho this might be right forCancer National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Study completedNCT03517488What this trial is testingXmAb®20717 in Subjects With Selected Advanced Solid TumorsWho this might be right forMelanomaBreast CarcinomaHepatocellular Carcinoma+25 more Xencor, Inc. 150
Not applicableLooking for participantsNCT07124000What this trial is testingDESTINY-PANTUMOUR04Who this might be right forAdenocarcinoma (NOS)Anal CancerBladder Cancer+24 more AstraZeneca 100
Not applicableStudy completedNCT00897442What this trial is testingCollecting Tumor Samples From Patients With Gynecological TumorsWho this might be right forBorderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical Adenocarcinoma+83 more Gynecologic Oncology Group 275
Not applicableLooking for participantsNCT05463796What this trial is testingInAdvance: Surveillance, Prevention, and Interception in a Population at Risk for CancerWho this might be right forCancer RiskCancer Predisposition SyndromeHereditary Cancer Prediction+28 more Dana-Farber Cancer Institute 5,000
Large-scale testing (Phase 3)Study completedNCT02997553What this trial is testingFluorescence for Sentinel Lymph Node Identification in Cancer SurgeryWho this might be right forBreast CarcinomaHead and Neck CancerMelanoma (Skin)+7 more Institut de Cancérologie de Lorraine 744
Testing effectiveness (Phase 2)WithdrawnNCT03220009What this trial is testingNivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWho this might be right forCervical CarcinomaEsophageal CarcinomaMucosal Melanoma+14 more National Cancer Institute (NCI)
Not applicableStudy completedNCT04028479What this trial is testingThe Registry of Oncology Outcomes Associated With Testing and TreatmentWho this might be right forAdenocarcinomaAdenocystic CarcinomaAnal Cancer+73 more Taproot Health 167
Large-scale testing (Phase 3)Study completedNCT00538850What this trial is testingFentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainWho this might be right forCancer INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Active Not RecruitingNCT05111574What this trial is testingUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryWho this might be right forAnal MelanomaBladder MelanomaCervical Melanoma+14 more National Cancer Institute (NCI) 101
Early research (Phase 1)Active Not RecruitingNCT05973487What this trial is testingA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsWho this might be right forHead and Neck CancerCervical CancerNon-small Cell Carcinoma+18 more TScan Therapeutics, Inc. 840
Not applicableUnknownNCT03896958What this trial is testingThe PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Who this might be right forCancer, All TypesCancer of LiverCancer of Stomach+42 more SpeciCare 1,000
Testing effectiveness (Phase 2)Study completedNCT05199584What this trial is testingA Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsWho this might be right forSolid Tumors With PTCH1 Loss-of-function Mutations Endeavor Biomedicines, Inc. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT02978625What this trial is testingTalimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersWho this might be right forAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine Carcinoma+36 more National Cancer Institute (NCI) 68
Testing effectiveness (Phase 2)Looking for participantsNCT05592626What this trial is testingA Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more Marengo Therapeutics, Inc. 366
Testing effectiveness (Phase 2)Looking for participantsNCT05969860What this trial is testingAt-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerWho this might be right forAdvanced Anal CarcinomaAdvanced Biliary Tract CarcinomaAdvanced Bladder Carcinoma+41 more Mayo Clinic 220
Not applicableStudy completedNCT05461430What this trial is testingMass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)Who this might be right forPleural Effusion, MalignantAscites, MalignantCarcinoma+29 more Travera Inc 72
Early research (Phase 1)Study completedNCT03849469What this trial is testingXmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsWho this might be right forMelanomaCervical CarcinomaPancreatic Carcinoma+20 more Xencor, Inc. 78
Not applicableStudy completedNCT01526486What this trial is testingVideoscopic Versus Open Inguinal Lymphadenectomy for CancerWho this might be right forMelanomaMerkel Cell CarcinomaSquamous Cell Carcinoma+8 more Emory University 29